As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

In 2024, China’s IVD market size is expected to be less than RMB 120 billion, remaining flat compared to 2023. Domestic brands account for approximately 50% of the market.

Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its liquid biopsy-based ExoDx Prostate IntelliScore (EPI) test in the state.

Beckman Coulter Life Sciences said today it has acquired single-cell data analysis and software-as-a-service company Cytobank for an undisclosed amount.

Resolution Bioscience is the latest in a long line of firms that has been granted breakthrough device designation from FDA. The Kirkland, WA-based company received the designation for its qualitative in vitro diagnostic.

A breach of Quest Diagnostics’ billing collections vendor could have exposed the personal, financial, and medical information of as many as 12 million customers, multiple media outlets are reporting.

There’s a new player in the liquid biopsy field. Thrive Earlier Detection Corp., announced late last month that it has launched and has raised $110 million in its Series A round.

Inivata has developed the InVision platform based on research from the Cancer Research UK Cambridge Institute at the University of Cambridge. Its lead product, InVisionFirst-Lung, is commercially available and was developed to provide molecu

The latest bit of activity comes from Saga Diagnostics, a Lund, Sweden based company that has raised $4.1 million in a financing round. In a release the company said Hadean Ventures, a Nordic focused European life science fund manager, leads

Liquid biopsy has attracted a surge of companies that are trying to change the way cancer is detected and monitored. But the benefits of this new type of technology can - and should - seep into other disease categories.

Upon closing of the transaction, Burlington, the MA-based company will be a subsidiary of Bracco Imaging, led by its current leadership team. Milan, Italy-based Bracco Imaging said Blue Earth Diagnostics will retain the well-established bran

The San Francisco-based company said it signed a definitive agreement to acquire Singular Bio for $55 million. Singular Bio specializes in developing single molecule detection technology that enables lower costs and expanded use of high-qual